Insider Selling: Moderna Inc (NASDAQ:MRNA) CEO Sells 19,000 Shares of Stock

Share on StockTwits

Moderna Inc (NASDAQ:MRNA) CEO Stephane Bancel sold 19,000 shares of the stock in a transaction dated Thursday, October 8th. The shares were sold at an average price of $72.42, for a total transaction of $1,375,980.00.

Stephane Bancel also recently made the following trade(s):

  • On Friday, October 2nd, Stephane Bancel sold 11,046 shares of Moderna stock. The stock was sold at an average price of $70.64, for a total transaction of $780,289.44.
  • On Wednesday, September 30th, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $72.72, for a total transaction of $654,480.00.
  • On Thursday, September 24th, Stephane Bancel sold 19,000 shares of Moderna stock. The stock was sold at an average price of $66.68, for a total transaction of $1,266,920.00.
  • On Monday, September 21st, Stephane Bancel sold 8,587 shares of Moderna stock. The stock was sold at an average price of $68.56, for a total transaction of $588,724.72.
  • On Friday, September 18th, Stephane Bancel sold 11,046 shares of Moderna stock. The shares were sold at an average price of $67.71, for a total value of $747,924.66.
  • On Wednesday, September 16th, Stephane Bancel sold 9,000 shares of Moderna stock. The stock was sold at an average price of $67.69, for a total value of $609,210.00.
  • On Friday, September 11th, Stephane Bancel sold 11,046 shares of Moderna stock. The shares were sold at an average price of $58.42, for a total value of $645,307.32.
  • On Friday, September 4th, Stephane Bancel sold 11,046 shares of Moderna stock. The stock was sold at an average price of $61.87, for a total value of $683,416.02.
  • On Wednesday, September 2nd, Stephane Bancel sold 18,247 shares of Moderna stock. The shares were sold at an average price of $63.22, for a total value of $1,153,575.34.
  • On Wednesday, August 26th, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $67.45, for a total transaction of $607,050.00.

Shares of NASDAQ:MRNA traded up $0.07 during trading on Friday, reaching $73.00. The company had a trading volume of 4,765,520 shares, compared to its average volume of 17,233,820. The company has a fifty day moving average of $66.53 and a two-hundred day moving average of $60.61. The company has a current ratio of 17.30, a quick ratio of 17.30 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $28.80 billion, a P/E ratio of -52.14 and a beta of 0.45. Moderna Inc has a 12 month low of $13.53 and a 12 month high of $95.21.

Moderna (NASDAQ:MRNA) last announced its earnings results on Wednesday, August 5th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.05. Moderna had a negative net margin of 461.42% and a negative return on equity of 27.85%. The company had revenue of $66.35 million during the quarter, compared to analyst estimates of $24.24 million. The firm’s revenue for the quarter was up 407.2% compared to the same quarter last year. As a group, equities research analysts predict that Moderna Inc will post -1.57 earnings per share for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. FMR LLC increased its position in shares of Moderna by 51.6% during the 2nd quarter. FMR LLC now owns 37,532,143 shares of the company’s stock valued at $2,409,938,000 after purchasing an additional 12,772,752 shares during the last quarter. Vanguard Group Inc. grew its position in Moderna by 24.5% during the second quarter. Vanguard Group Inc. now owns 25,625,532 shares of the company’s stock valued at $1,645,416,000 after acquiring an additional 5,045,279 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. bought a new position in Moderna during the second quarter valued at approximately $68,886,000. Swiss National Bank purchased a new position in shares of Moderna during the second quarter worth approximately $66,194,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Moderna by 43.0% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 1,456,015 shares of the company’s stock worth $93,491,000 after acquiring an additional 438,140 shares during the last quarter. Hedge funds and other institutional investors own 55.04% of the company’s stock.

Several research analysts recently commented on the stock. Chardan Capital cut their price objective on shares of Moderna from $95.00 to $93.00 and set a “buy” rating for the company in a report on Thursday. Brookline Capital Management reiterated a “buy” rating and issued a $95.00 price target on shares of Moderna in a research report on Monday, July 13th. SunTrust Banks began coverage on Moderna in a research note on Monday, July 27th. They set a “buy” rating and a $120.00 price objective on the stock. Jefferies Financial Group restated a “buy” rating and issued a $90.00 target price on shares of Moderna in a research note on Wednesday, August 12th. Finally, Oppenheimer reaffirmed a “buy” rating and set a $108.00 target price on shares of Moderna in a report on Wednesday, August 12th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and sixteen have issued a buy rating to the company. Moderna has a consensus rating of “Buy” and a consensus price target of $87.33.

Moderna Company Profile

Moderna, Inc, a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Further Reading: Understanding Market Liquidity

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.